MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas

Neurologia Medico-chirurgica
Hideaki AbeYukihiko Fujii

Abstract

Histone H3 mutations are frequently found in diffuse midline gliomas (DMGs), which include diffuse intrinsic pontine gliomas and thalamic gliomas. These tumors have dismal prognoses. Recent evidence suggests that one reason for the poor prognoses is that O6-methylguanine-DNA methyltransferase (MGMT) promoter frequently lacks methylation in DMGs. This review compares the epigenetic changes brought about by histone mutations to those by isocitrate dehydrogenase-mutant gliomas, which frequently have methylated MGMT promoters and are known to be sensitive to temozolomide.

References

Sep 30, 2004·International Journal of Cancer. Journal International Du Cancer·Maria MöllemannGuido Reifenberger
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Mar 3, 2006·The Lancet Oncology·Darren HargraveEric Bouffet
May 8, 2007·DNA Repair·Filipe V Jacinto, Manel Esteller
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maryam ZarghooniCynthia Hawkins
Nov 9, 2011·Neuro-oncology·Katherine E WarrenPaul S Meltzer
Mar 7, 2012·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Junichi YoshimuraGeorge I Jallo
Apr 10, 2012·Brain Tumor Pathology·Hidehiro OkaKiyotaka Fujii
Nov 29, 2013·Neuro-oncology·Koki AiharaNobuhito Saito
Jan 25, 2014·Nature Reviews. Cancer·Pierre G CoulieThierry Boon
Apr 8, 2014·Nature Genetics·Adam M FontebassoMark W Kieran
Apr 8, 2014·Nature Genetics·Kathryn R TaylorJacques Grill
Jul 22, 2014·Nature·Theresa SchumacherMichael Platten
May 6, 2015·Nature Medicine·Catherine S GrassoMichelle Monje
May 8, 2015·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Ryosuke OguraAkiyoshi Kakita
Apr 25, 2017·Cancer Cell·Surya NagarajaMichelle Monje
Jun 9, 2017·Neurologia Medico-chirurgica·Rintaro Hashizume
Aug 16, 2017·Oncoimmunology·Katharina OchsMichael Platten
Oct 4, 2017·Neurosurgery·Yoshua EsquenaziViviane Tabar
Dec 6, 2017·The Journal of Experimental Medicine·Zinal S ChhedaHideho Okada
Dec 6, 2017·Oncology Reports·Patrick C FlanneryAdam L Green
Dec 17, 2017·Acta Neuropathologica Communications·Rouzbeh BananChristian Hartmann

❮ Previous
Next ❯

Methods Mentioned

BETA
histone acetylation
acetylation
xenografts

Clinical Trials Mentioned

NCT02960230

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.